Results 31 to 40 of about 1,266 (177)

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD

open access: yesTherapeutics and Clinical Risk Management, 2015
Girolamo Pelaia,1 Alessandro Vatrella,2 Maria Teresa Busceti,1 Luca Gallelli,3 Cecilia Calabrese,4 Rosa Terracciano,3 Nicola Lombardo,1 Rosario Maselli11Department of Medical and Surgical Sciences, Magna Græcia University of Catanzaro, Catanzaro ...
Pelaia G   +7 more
doaj   +5 more sources

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)

open access: yesInternational Journal of COPD, 2016
Kai-Michael Beeh,1 Eric Derom,2 José Echave-Sustaeta,3 Lars Grönke,4 Alan Hamilton,5 Dongmei Zhai,6 Leif Bjermer71Insaf GmbH Institut für Atemwegsforschung, Wiesbaden, Germany; 2Department of Internal Medicine, Ghent University Hospital,
Beeh KM   +6 more
doaj   +1 more source

Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies

open access: yesInternational Journal of COPD, 2018
Craig LaForce,1 Eric Derom,2 Ulrich Bothner,3 Isabel M Kloer,3 Matthias Trampisch,4 Roland Buhl5 1NC Clinical Research, Raleigh, NC, USA; 2Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; 3Pharmacovigilance, Boehringer ...
LaForce C   +5 more
doaj   +1 more source

The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies

open access: yesInternational Journal of COPD, 2016
Masakazu Ichinose,1 Hiroyuki Taniguchi,2 Ayako Takizawa,3 Lars Grönke,4 Lazaro Loaiza,4 Florian Voß,4 Yihua Zhao,5 Yoshinosuke Fukuchi61Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan ...
Ichinose M   +7 more
doaj   +1 more source

Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease

open access: yesExpert Review of Clinical Pharmacology, 2015
A solid scientific rationale and an increasing body of clinical evidence for combining a β2-agonist with an antimuscarinic agent in COPD fully support the opinion that patients not controlled by a single bronchodilator should be given two bronchodilators
Cazzola, Mario   +7 more
core   +6 more sources

Tiotropium/Olodaterol treatment reduces cigarette smoke extract-induced cell death in BEAS-2B bronchial epithelial cells

open access: yesBMC Pharmacology and Toxicology, 2020
Background Cigarette smoking is a critical risk factor for the destruction of lung parenchyma or the development of emphysema, which is characteristic of COPD.
Cheng-hsiung Chen   +6 more
doaj   +1 more source

Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

open access: yesBMJ Open, 2021
Objectives Chronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single ...
Maureen Rutten-van Mölken   +6 more
doaj   +1 more source

Predicting the duration of action of β2‐adrenergic receptor agonists: Ligand and structure‐based approaches

open access: yesMolecular Informatics, Volume 42, Issue 12, December 2023., 2023
Abstract Agonists of the β2 adrenergic receptor (ADRB2) are an important class of medications used for the treatment of respiratory diseases. They can be classified as short acting (SABA) or long acting (LABA), with each class playing a different role in patient management.
Luca Chiesa   +2 more
wiley   +1 more source

Honokiol ameliorates cigarette smoke‐induced damage of airway epithelial cells via the SIRT3/SOD2 signalling pathway

open access: yesJournal of Cellular and Molecular Medicine, Volume 27, Issue 24, Page 4009-4020, December 2023., 2023
Abstract Cigarette smoking can cause damage of airway epithelial cells and contribute to chronic obstructive pulmonary disease (COPD). Honokiol is originally isolated from Magnolia obovata with multiple biological activities. Here, we investigated the protective effects of honokiol on cigarette smoke extract (CSE)‐induced injury of BEAS‐2B cells.
Fei Li   +4 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors

open access: yesBritish Journal of Pharmacology, Volume 180, Issue S2, Page S23-S144, October 2023., 2023
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands.
Stephen P. H. Alexander   +165 more
wiley   +1 more source

Home - About - Disclaimer - Privacy